NASDAQ:IFRX InflaRx (IFRX) Stock Price, News & Analysis → They said crypto was dead. It went up 100X. (From InvestorPlace) (Ad) Free IFRX Stock Alerts $1.50 -0.08 (-5.06%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$1.50▼$1.5750-Day Range$1.47▼$2.0352-Week Range$1.14▼$7.25Volume149,419 shsAverage Volume241,840 shsMarket Capitalization$67.05 millionP/E RatioN/ADividend YieldN/APrice Target$11.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get InflaRx alerts: Email Address InflaRx MarketRank™ Stock AnalysisAnalyst RatingBuy3.25 Rating ScoreUpside/Downside677.8% Upside$11.67 Price TargetShort InterestHealthy0.66% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.74) to ($0.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.87 out of 5 starsMedical Sector242nd out of 947 stocksPharmaceutical Preparations Industry110th out of 435 stocks 3.6 Analyst's Opinion Consensus RatingInflaRx has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.67, InflaRx has a forecasted upside of 677.8% from its current price of $1.50.Amount of Analyst CoverageInflaRx has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.66% of the outstanding shares of InflaRx have been sold short.Short Interest Ratio / Days to CoverInflaRx has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InflaRx has recently decreased by 9.35%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldInflaRx does not currently pay a dividend.Dividend GrowthInflaRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IFRX. Previous Next 4.1 News and Social Media Coverage News SentimentInflaRx has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for InflaRx this week, compared to 1 article on an average week.Search Interest3 people have searched for IFRX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows3 people have added InflaRx to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, InflaRx insiders have not sold or bought any company stock.Percentage Held by Insiders16.30% of the stock of InflaRx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions48.23% of the stock of InflaRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for InflaRx are expected to grow in the coming year, from ($0.74) to ($0.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of InflaRx is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of InflaRx is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInflaRx has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThe only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.Get the stock ticker here >>> About InflaRx Stock (NASDAQ:IFRX)InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.Read More IFRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IFRX Stock News HeadlinesMarch 6, 2024 | finance.yahoo.comIs InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?February 22, 2024 | investing.comInflaRx N.V. (IFRX)March 19, 2024 | The Bull Report (Ad)The AI Bottleneck No One is Talking AboutRenewable energy is growing at an impressive speed - but not fast enough. This could be one of the greatest periods for the nuclear industry ever.February 22, 2024 | finance.yahoo.comInflaRx Appoints Jan Medina as Head of Investor RelationsFebruary 22, 2024 | globenewswire.comInflaRx Appoints Jan Medina as Head of Investor RelationsFebruary 17, 2024 | finance.yahoo.comIFRX Apr 2024 2.500 callJanuary 25, 2024 | markets.businessinsider.comBuy Recommendation for InflaRx Amidst Strategic Initiatives and Promising Clinical AdvancesJanuary 25, 2024 | finanznachrichten.deInflaRx N.V.: InflaRx Announces Initiation of its Commitment Program for GOHIBIC(vilobelimab) to Help Broaden Access for Eligible PatientsMarch 19, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… January 25, 2024 | finance.yahoo.comInflaRx N.V.'s (NASDAQ:IFRX) top owners are individual investors with 55% stake, while 23% is held by institutionsJanuary 25, 2024 | finance.yahoo.comInflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible PatientsJanuary 6, 2024 | markets.businessinsider.comInflaRx’s Promising INF904 Phase 1 Results Prompt Buy RatingJanuary 4, 2024 | finanznachrichten.deInflaRx N.V.: InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904January 4, 2024 | markets.businessinsider.comInflaRx's MAD Part Phase 1 Trial For INF904 Reports Positive ResultsJanuary 4, 2024 | finance.yahoo.comInflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904December 1, 2023 | finance.yahoo.comHere's Why InflaRx N.V. (IFRX) Looks Ripe for Bottom FishingNovember 28, 2023 | finance.yahoo.comAfter Plunging -17.65% in 4 Weeks, Here's Why the Trend Might Reverse for InflaRx N.V. (IFRX)November 20, 2023 | morningstar.comInflaRx NV IFRXNovember 7, 2023 | markets.businessinsider.comBuy Rating for InflaRx: Potential Breakthrough PG Treatment and Promising Revenue ForecastsNovember 6, 2023 | finance.yahoo.comInflaRx N.V. (IFRX) Loses -47.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerNovember 6, 2023 | finance.yahoo.comInflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma GangrenosumNovember 3, 2023 | msn.comIFRX, LIXT and IOAC are among pre market gainersNovember 3, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cross Country Healthcare (CCRN), InflaRx (IFRX) and Elevation Oncology (ELEV)November 1, 2023 | finanznachrichten.deInflaRx N.V.: InflaRx Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 1, 2023 | msn.comInflaRx GAAP EPS of -€0.13November 1, 2023 | finance.yahoo.comInflaRx Reports Third Quarter 2023 Financial Results and Provides Business UpdateOctober 10, 2023 | finance.yahoo.comLoss-Making InflaRx N.V. (NASDAQ:IFRX) Expected To Breakeven In The Medium-TermSee More Headlines Receive IFRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InflaRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/12/2021Today3/18/2024Next Earnings (Estimated)3/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IFRX CUSIPN/A CIK1708688 Webwww.inflarx.de Phone493641508180FaxN/AEmployees44Year FoundedN/APrice Target and Rating Average Stock Price Target$11.67 High Stock Price Target$19.00 Low Stock Price Target$8.00 Potential Upside/Downside+677.8%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,070,000.00 Net MarginsN/A Pretax Margin-55,786.37% Return on Equity-33.62% Return on Assets-30.53% Debt Debt-to-Equity RatioN/A Current Ratio11.93 Quick Ratio11.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.08 per share Price / Book0.72Miscellaneous Outstanding Shares44,700,000Free Float37,417,000Market Cap$67.05 million OptionableOptionable Beta1.29 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Niels C. Riedemann M.D. (Age 51)Ph.D., Co-Founder, CEO & Executive Director Prof. Renfeng Guo M.D. (Age 54)Co-Founder, Chief Scientific Officer & Executive Director Dr. Thomas Taapken Ph.D. (Age 59)Chief Financial Officer Key CompetitorsAssembly BiosciencesNASDAQ:ASMBEliem TherapeuticsNASDAQ:ELYMMediciNovaNASDAQ:MNOVKezar Life SciencesNASDAQ:KZREyenoviaNASDAQ:EYENView All CompetitorsInstitutional OwnershipCitadel Advisors LLCSold 2,600 shares on 2/15/2024Ownership: 0.000%Point72 Asset Management L.P.Bought 125,600 shares on 2/14/2024Ownership: 4.937%Affinity Asset Advisors LLCSold 125,000 shares on 2/13/2024Ownership: 0.448%Northern Trust CorpBought 39,130 shares on 2/13/2024Ownership: 0.088%Franklin Street Advisors Inc. NCBought 25,000 shares on 1/18/2024Ownership: 0.168%View All Institutional Transactions IFRX Stock Analysis - Frequently Asked Questions Should I buy or sell InflaRx stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InflaRx in the last twelve months. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IFRX shares. View IFRX analyst ratings or view top-rated stocks. What is InflaRx's stock price target for 2024? 4 Wall Street analysts have issued 12 month price targets for InflaRx's stock. Their IFRX share price targets range from $8.00 to $19.00. On average, they anticipate the company's stock price to reach $11.67 in the next twelve months. This suggests a possible upside of 677.8% from the stock's current price. View analysts price targets for IFRX or view top-rated stocks among Wall Street analysts. How have IFRX shares performed in 2024? InflaRx's stock was trading at $1.63 at the beginning of the year. Since then, IFRX shares have decreased by 8.0% and is now trading at $1.50. View the best growth stocks for 2024 here. Are investors shorting InflaRx? InflaRx saw a drop in short interest in the month of February. As of February 29th, there was short interest totaling 293,900 shares, a drop of 9.3% from the February 14th total of 324,200 shares. Based on an average daily volume of 278,300 shares, the short-interest ratio is presently 1.1 days. View InflaRx's Short Interest. When is InflaRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024. View our IFRX earnings forecast. How were InflaRx's earnings last quarter? InflaRx (NASDAQ:IFRX) announced its quarterly earnings results on Wednesday, May, 12th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. What ETF holds InflaRx's stock? Amplify Treatments, Testing and Advancements ETF holds 15,278 shares of IFRX stock, representing 0.37% of its portfolio. What other stocks do shareholders of InflaRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other InflaRx investors own include Dynavax Technologies (DVAX), Gilead Sciences (GILD), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), AbbVie (ABBV), OPKO Health (OPK), Capricor Therapeutics (CAPR), Citius Pharmaceuticals (CTXR), Kadmon (KDMN) and Moderna (MRNA). When did InflaRx IPO? (IFRX) raised $100 million in an IPO on Wednesday, November 8th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. Who are InflaRx's major shareholders? InflaRx's stock is owned by many different institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (4.94%), Raymond James Financial Services Advisors Inc. (0.71%), Affinity Asset Advisors LLC (0.45%), Raymond James & Associates (0.39%), Franklin Street Advisors Inc. NC (0.17%) and Northern Trust Corp (0.09%). How do I buy shares of InflaRx? Shares of IFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IFRX) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.